Related Experiment Video

Updated: Aug 17, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression

Nathalie Heuzé-Vourc'h1, Ming Liu, Harnisha Dalwadi

  • 1Division of Pulmonary and Critical Care Medicine, Department of Medicine, UCLA, Los Angeles, CA, USA.

Biochemical and Biophysical Research Communications
|June 14, 2005
PubMed

Insights

Interleukin-20 (IL-20) inhibits cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) production, thereby reducing angiogenesis in lung cancer cells. This discovery highlights IL-20 as a potential therapeutic target for non-small cell lung cancer.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Cyclooxygenase-2 (COX-2) overexpression and prostaglandin E2 (PGE2) production are linked to non-small cell lung cancer (NSCLC) and promote tumor angiogenesis.
  • Understanding the regulatory mechanisms of COX-2/PGE2 in NSCLC is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the role of Interleukin-20 (IL-20) in regulating COX-2 and PGE2 expression in lung cancer.
  • To determine the anti-angiogenic effects of IL-20 and its underlying molecular pathways.

Main Methods:

  • Utilized human bronchial epithelial and endothelial cells for in vitro studies.
  • Employed flow cytometry to analyze IL-20's effect on COX-2/PGE2 pathways.
  • Assessed IL-20's impact on experimental angiogenesis, including PMA-induced angiogenesis.

Main Results:

  • IL-20 was found to downregulate COX-2 and PGE2 in human bronchial epithelial and endothelial cells.
  • IL-20-mediated inhibition of COX-2/PGE2 involves the IL-22R1/IL-20R2 receptor complex.
  • IL-20 demonstrated significant anti-angiogenic effects, inhibiting experimental angiogenesis via the COX-2 regulatory pathway.

Conclusions:

  • IL-20 acts as a negative modulator of COX-2/PGE2 signaling.
  • IL-20 possesses anti-angiogenic properties, offering a potential therapeutic strategy for NSCLC.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...